organization · Reporting owner
Atlas Venture Fund XI, L.P.
Disclosed activity across 8 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akero Therapeutics, Inc.AKRO · Entity 71984 | 10% owner | December 31, 2019 | January 02, 2020 |
| Day One Biopharmaceuticals, Inc.DAWN · Entity 51180 | 10% owner | December 12, 2022 | December 14, 2022 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | 10% owner | February 26, 2024 | February 28, 2024 |
| ImageneBio, Inc.IKNA · Entity 7139 | 10% owner | March 30, 2021 | December 15, 2021 |
| Korro Bio, Inc.KRRO · Entity 6388 | 10% owner | November 03, 2023 | November 07, 2023 |
| Third Harmonic Bio, Inc.THRD · Entity 76517 | 10% owner | November 01, 2024 | November 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akero Therapeutics, Inc.
Report date December 31, 2019 · Filed January 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,706,412 |
Reported balance
After 2019-12-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-12-31 · Other · Disposed 242,883 · Balance 2,706,412 F1: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XI, L.P. ("AVF XI") to its general partner and limited partners without additional consideration, pursuant to AVF XI's 10b5-1 plan dated July 26, 2019. F2: These shares are owned directly by AVF XI. Atlas Venture Associates XI, L.P., ("AVA XI LP") is the general partner of AVF XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVF XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XI, L.P. ("AVF XI") to its general partner and limited partners without additional consideration, pursuant to AVF XI's 10b5-1 plan dated July 26, 2019.
F2: These shares are owned directly by AVF XI. Atlas Venture Associates XI, L.P., ("AVA XI LP") is the general partner of AVF XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVF XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.
Day One Biopharmaceuticals, Inc.
Report date December 12, 2022 · Filed December 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,008,534 |
Reported balance
After 2022-12-12 transaction · row 1
1 source rowRow 1 · 2022-12-12 · Other · Disposed 600,854 · Balance 6,008,534 F1: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI") to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted by Atlas Venture Fund XI pursuant to Rule 10b5-1 on August 19, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI") to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted by Atlas Venture Fund XI pursuant to Rule 10b5-1 on August 19, 2022.
Dyne Therapeutics, Inc.
Report date February 26, 2024 · Filed February 28, 2024
Jointly reported with Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,698,091 |
Last balance in matching sequence
After 2024-02-28 transaction · row 14
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2024-02-26 · Sale · Disposed 136,312 · Balance 6,216,250 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12). F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Row 2 · 2024-02-26 · Sale · Disposed 64,783 · Balance 6,151,467 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive. F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Row 7 · 2024-02-27 · Sale · Disposed 272,923 · Balance 5,878,544 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive. F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Row 8 · 2024-02-27 · Sale · Disposed 25,779 · Balance 5,852,765 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive. F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Row 13 · 2024-02-28 · Sale · Disposed 152,244 · Balance 5,700,521 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive. F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Row 14 · 2024-02-28 · Sale · Disposed 2,430 · Balance 5,698,091 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive. F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,564,932 |
Reported balance
After 2024-02-26 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-02-26 · Sale · Disposed 20,205 · Balance 1,564,932 F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12). F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,555,329 |
Reported balance
After 2024-02-26 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2024-02-26 · Sale · Disposed 9,603 · Balance 1,555,329 F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive. F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 909,107 |
Reported balance
After 2024-02-26 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2024-02-26 · Sale · Disposed 11,736 · Balance 909,107 F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12). F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 903,527 |
Reported balance
After 2024-02-26 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2024-02-26 · Sale · Disposed 5,580 · Balance 903,527 F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive. F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,514,874 |
Reported balance
After 2024-02-27 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2024-02-27 · Sale · Disposed 40,455 · Balance 1,514,874 F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive. F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,511,053 |
Reported balance
After 2024-02-27 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2024-02-27 · Sale · Disposed 3,821 · Balance 1,511,053 F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive. F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 880,022 |
Reported balance
After 2024-02-27 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2024-02-27 · Sale · Disposed 23,505 · Balance 880,022 F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive. F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 877,806 |
Reported balance
After 2024-02-27 transaction · row 12
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 12 · 2024-02-27 · Sale · Disposed 2,216 · Balance 877,806 F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive. F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,488,486 |
Reported balance
After 2024-02-28 transaction · row 15
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 15 · 2024-02-28 · Sale · Disposed 22,567 · Balance 1,488,486 F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive. F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,488,126 |
Reported balance
After 2024-02-28 transaction · row 16
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 16 · 2024-02-28 · Sale · Disposed 360 · Balance 1,488,126 F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive. F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 864,697 |
Reported balance
After 2024-02-28 transaction · row 17
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 17 · 2024-02-28 · Sale · Disposed 13,109 · Balance 864,697 F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive. F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 864,487 |
Reported balance
After 2024-02-28 transaction · row 18
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 18 · 2024-02-28 · Sale · Disposed 210 · Balance 864,487 F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive. F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12).
F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive.
F5: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.
F6: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.
F7: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.
F8: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive.
ImageneBio, Inc.
Report date March 30, 2021 · Filed December 15, 2021
Jointly reported with Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 874,634 |
Reported balance
After 2021-03-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-03-30 · Purchase · Acquired 125,000 · Balance 874,634 F1: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | Direct | 1,241,935 |
Last balance in matching sequence
After 2021-12-14 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2021-12-10 · Sale · Disposed 11,989 · Balance 1,256,224 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4). F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Row 3 · 2021-12-13 · Sale · Disposed 8,330 · Balance 1,247,894 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive. F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Row 4 · 2021-12-14 · Sale · Disposed 5,959 · Balance 1,241,935 F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).
F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive.
Korro Bio, Inc.
Report date November 03, 2023 · Filed November 07, 2023
Jointly reported with Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 177,217 |
Reported balance
Holding disclosure · report date 2023-11-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 177,217 F1: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 942,075 |
Reported balance
Holding disclosure · report date 2023-11-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 942,075 F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.
F2: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.
Third Harmonic Bio, Inc.
Report date November 01, 2024 · Filed November 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,798,075 |
Reported balance
After 2024-11-01 transaction · row 1
1 source rowRow 1 · 2024-11-01 · Other · Disposed 515,688 · Balance 9,798,075 F1: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI") to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted by Atlas Venture Fund XI pursuant to Rule 10b5-1 on September 26, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI") to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted by Atlas Venture Fund XI pursuant to Rule 10b5-1 on September 26, 2024.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sionna Therapeutics, Inc.
Report date February 10, 2025 · Filed February 10, 2025
Jointly reported with Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LP, Atlas Venture Associates Opportunity II, LLC
Section 16 reporting ended · disclosed 2025-02-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,886,293 |
Reported balance
After 2025-02-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-02-10 · Conversion · Acquired 2,886,293 · Balance 2,886,293 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Atlas Venture Opportunity Fund II, L.P. | 807,727 |
Last balance in matching sequence
After 2025-02-10 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2025-02-10 · Conversion · Acquired 747,727 · Balance 747,727 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Row 3 · 2025-02-10 · Purchase · Acquired 60,000 · Balance 807,727 F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
| Series Seed convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-02-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-10 · Conversion · Disposed 1,051,051 · Balance 0 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. |
| Series A convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-02-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-10 · Conversion · Disposed 1,806,317 · Balance 0 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-02-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-02-10 · Conversion · Disposed 1,298,332 · Balance 0 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. |
| Series C convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-02-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-10 · Conversion · Disposed 61,463 · Balance 0 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. |
| Series C convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Atlas Venture Opportunity Fund II, L.P. | 0 |
Reported balance
After 2025-02-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-10 · Conversion · Disposed 1,092,504 · Balance 0 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.
F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.
F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.
Xilio Therapeutics, Inc.
Report date February 08, 2024 · Filed February 09, 2024
Jointly reported with Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC
Section 16 reporting ended · disclosed 2024-02-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,019,563 |
Reported balance
After 2024-02-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-02-08 · Sale · Disposed 733 · Balance 2,019,563 F1: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 734,546 |
Reported balance
After 2024-02-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-02-08 · Sale · Disposed 267 · Balance 734,546 F2: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.
F2: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2022 Filed Sep 19, 2022 16:51 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | ConversionCommon Stock | 594,096 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-050535 · doc4.xml · nonDerivative · entry 3 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date. F4 · ownership.direct: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 19, 2022 Filed Sep 19, 2022 16:51 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | PurchaseCommon Stock | 300,000 | $17.00 | $5,100,000.00 |
DisclosureSEC source: 0001209191-22-050535 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,313,763 F3 · price: On September 19, 2022, Atlas Venture Fund XI purchased 300,000 shares of common stock of the Issuer at a purchase price of $17.00 per share pursuant to an underwritten public offering. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 19, 2022 Filed Sep 19, 2022 16:51 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | ConversionCommon Stock | 6,472,374 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-050535 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,013,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, and Series B Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock based on a 1 to 2.259 reverse stock conversion ratio immediately prior to the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:58 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | OtherCommon Stock | 600,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050928 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,609,388 F1 · kind: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI") to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted by Atlas Venture Fund XI pursuant to Rule 10b5-1 on August 19, 2022. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 21:09 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseCommon Stock | 766,667 | $15.00 | $11,500,005.00 |
DisclosureSEC source: 0001209191-22-038713 · doc4.xml · nonDerivative · entry 1 Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 766,667 F1 · ownership.direct: The shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| December 14, 2021 Filed Dec 15, 2021 01:27 UTC | ImageneBio, Inc. IKNA · Entity 7139 | SaleCommon Stock | 5,959 | $14.00 | $83,426.00 |
DisclosureSEC source: 0001209191-21-069644 · doc4.xml · nonDerivative · entry 4 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,241,935 F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 01:27 UTC | ImageneBio, Inc. IKNA · Entity 7139 | SaleCommon Stock | 8,330 | $14.64 | $121,951.20 |
DisclosureSEC source: 0001209191-21-069644 · doc4.xml · nonDerivative · entry 3 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,247,894 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $14.65 inclusive. F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| December 10, 2021 Filed Dec 15, 2021 01:27 UTC | ImageneBio, Inc. IKNA · Entity 7139 | SaleCommon Stock | 11,989 | $15.03 | $180,194.67 |
DisclosureSEC source: 0001209191-21-069644 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,256,224 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.55 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4). F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 22:30 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | OtherCommon Stock | 801,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-067018 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,210,242 F1 · kind: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI") to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted by Atlas Venture Fund XI pursuant to Rule 10b5-1 on July 16, 2021. Read SEC document |
| October 26, 2021 Filed Oct 26, 2021 21:01 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionSeries C Preferred Stock · Derivative | 5,210,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-130026 · tm2130646-24_4seq1.xml · derivative · entry 7 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 548,442 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F4 · price: The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F4 · derivative.exercise_date: The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F4 · derivative.expiration_date: The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F5 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| October 26, 2021 Filed Oct 26, 2021 21:01 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionSeries B Preferred Stock · Derivative | 5,928,852 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-130026 · tm2130646-24_4seq1.xml · derivative · entry 6 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 624,089 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F3 · price: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F3 · derivative.exercise_date: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F3 · derivative.expiration_date: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| October 26, 2021 Filed Oct 26, 2021 21:01 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionSeries A1 Preferred Stock · Derivative | 13,043,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-130026 · tm2130646-24_4seq1.xml · derivative · entry 5 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,372,998 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A1 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A1 Preferred Stock had no expiration date. F1 · price: The Series A1 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A1 Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A1 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A1 Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A1 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A1 Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| October 26, 2021 Filed Oct 26, 2021 21:01 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | PurchaseCommon Stock | 187,500 | $16.00 | $3,000,000.00 |
DisclosureSEC source: 0001104659-21-130026 · tm2130646-24_4seq1.xml · nonDerivative · entry 4 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 735,942 F5 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| October 26, 2021 Filed Oct 26, 2021 21:01 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionCommon Stock | 548,442 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-130026 · tm2130646-24_4seq1.xml · nonDerivative · entry 3 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 548,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date. F5 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| October 26, 2021 Filed Oct 26, 2021 21:01 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionCommon Stock | 624,089 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-130026 · tm2130646-24_4seq1.xml · nonDerivative · entry 2 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,023,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| October 26, 2021 Filed Oct 26, 2021 21:01 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | ConversionCommon Stock | 1,372,998 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-130026 · tm2130646-24_4seq1.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,399,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A1 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A1 Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| July 13, 2021 Filed Jul 15, 2021 20:33 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | OtherCommon Stock | 814,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-046784 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,326,117 F1 · kind: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI") to its general partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted by Atlas Venture Fund XI pursuant to Rule 10b5-1 on June 11, 2021. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | ConversionSeries B Preferred Stock · Derivative | 741,396 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037402 · doc4.xml · derivative · entry 7 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 741,396 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The shares of the Issuer's Series B Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.exercise_date: The shares of the Issuer's Series B Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F3 · derivative.expiration_date: The shares of the Issuer's Series B Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | ConversionSeries A Preferred Stock · Derivative | 7,761,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037402 · doc4.xml · derivative · entry 6 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 7,761,380 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Series A Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-255754) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.exercise_date: The shares of the Issuer's Series A Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-255754) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F1 · derivative.expiration_date: The shares of the Issuer's Series A Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-255754) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Fund XI"). The general partner of Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseCommon Stock | 250,000 | $16.00 | $4,000,000.00 |
DisclosureSEC source: 0001209191-21-037402 · doc4.xml · nonDerivative · entry 4 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 250,000 F6 · shares: On June 1, 2021, Atlas Venture Opportunity Fund I purchased 250,000 shares of common stock of the Issuer at a purchase price of $16.00 per share pursuant to an underwritten public offering. F4 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseCommon Stock | 250,000 | $16.00 | $4,000,000.00 |
DisclosureSEC source: 0001209191-21-037402 · doc4.xml · nonDerivative · entry 3 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 250,000 F5 · shares: On June 1, 2021, Fund XI purchased 250,000 shares of common stock of the Issuer at a purchase price of $16.00 per share pursuant to an underwritten public offering. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Fund XI"). The general partner of Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | ConversionCommon Stock | 741,396 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037402 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 741,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The shares of the Issuer's Series B Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date. F4 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | ConversionCommon Stock | 7,761,380 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037402 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,761,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-255754) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Fund XI"). The general partner of Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:16 UTC | ImageneBio, Inc. IKNA · Entity 7139 | ConversionSeries B Preferred Stock · Derivative | 5,362,888 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014389 · doc4.xml · derivative · entry 7 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 749,634 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F4 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:16 UTC | ImageneBio, Inc. IKNA · Entity 7139 | ConversionSeries A-2 Preferred Stock · Derivative | 7,863,094 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014389 · doc4.xml · derivative · entry 6 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,099,118 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("Associates XI") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("Associates XI LLC") is the general partner of Associates XI. Each of Associates XI and Associates XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:16 UTC | ImageneBio, Inc. IKNA · Entity 7139 | ConversionSeries A-1 Preferred Stock · Derivative | 11,258,117 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014389 · doc4.xml · derivative · entry 5 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,573,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:16 UTC | ImageneBio, Inc. IKNA · Entity 7139 | ConversionSeries A Preferred Stock · Derivative | 9,499,999 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014389 · doc4.xml · derivative · entry 4 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,327,927 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:16 UTC | ImageneBio, Inc. IKNA · Entity 7139 | ConversionCommon Stock | 749,634 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014389 · doc4.xml · nonDerivative · entry 3 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 749,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F4 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:16 UTC | ImageneBio, Inc. IKNA · Entity 7139 | ConversionCommon Stock | 1,099,118 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014389 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,268,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3 · ownership.nature: These shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas XI"). Atlas Venture Associates XI, L.P. ("Associates XI") is the general partner of Atlas XI. Atlas Venture Associates XI, LLC ("Associates XI LLC") is the general partner of Associates XI. Each of Associates XI and Associates XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:16 UTC | ImageneBio, Inc. IKNA · Entity 7139 | ConversionCommon Stock | 2,901,609 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014389 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,901,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-7.154 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 30, 2021 Filed Dec 15, 2021 01:27 UTC | ImageneBio, Inc. IKNA · Entity 7139 | PurchaseCommon Stock | 125,000 | $16.00 | $2,000,000.00 |
DisclosureSEC source: 0001209191-21-069644 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 874,634 F1 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 01, 2021 Filed Jun 2, 2021 22:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseSeries B Preferred Stock · Derivative | 741,396 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037402 · doc4.xml · derivative · entry 5 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 741,396 Underlying: Common Stock · 741,396 shares Expires not disclosed F7 · derivative.exercise_price: The Reporting Person is reporting the purchase of these securities pursuant to Rule 16a-2(a) of the Securities Exchange Act of 1934, as amended. Each share of Series B Preferred Stock automatically converted into one share of Common Stock at the close of the Issuer's IPO and has no expiration date. F7 · derivative.exercise_date: The Reporting Person is reporting the purchase of these securities pursuant to Rule 16a-2(a) of the Securities Exchange Act of 1934, as amended. Each share of Series B Preferred Stock automatically converted into one share of Common Stock at the close of the Issuer's IPO and has no expiration date. F7 · derivative.expiration_date: The Reporting Person is reporting the purchase of these securities pursuant to Rule 16a-2(a) of the Securities Exchange Act of 1934, as amended. Each share of Series B Preferred Stock automatically converted into one share of Common Stock at the close of the Issuer's IPO and has no expiration date. F4 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 22:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | ConversionSeries B Preferred Stock · Derivative | 5,336,179 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026171 · doc4.xml · derivative · entry 4 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,608,785 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · derivative.exercise_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · derivative.expiration_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 22:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | ConversionSeries A Preferred Stock · Derivative | 20,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026171 · doc4.xml · derivative · entry 3 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 6,029,726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 22:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | ConversionCommon Stock | 1,608,785 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-026171 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,608,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 22:56 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | ConversionCommon Stock | 6,029,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-026171 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 8,140,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 21, 2020, the Series A Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 17:19 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | OtherCommon Stock | 242,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000396 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,706,412 F1 · kind: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XI, L.P. ("AVF XI") to its general partner and limited partners without additional consideration, pursuant to AVF XI's 10b5-1 plan dated July 26, 2019. F2 · ownership.nature: These shares are owned directly by AVF XI. Atlas Venture Associates XI, L.P., ("AVA XI LP") is the general partner of AVF XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVF XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:34 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | OtherCommon Stock | 50,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061376 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 454,589 F3 · kind: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Opportunity Fund I, L.P. ("AVO I") to its general partner and limited partners without additional consideration, pursuant to the AVO I's 10b5-1 plan dated July 26, 2019. F4 · ownership.nature: These shares are owned directly by AVO I. Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVO I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVO I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:34 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | OtherCommon Stock | 520,464 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061376 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,949,295 F1 · kind: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XI, L.P. ("AVF XI") to its general partner and limited partners without additional consideration, pursuant to the AVF XI's 10b5-1 plan dated July 26, 2019. F2 · ownership.nature: These shares are owned directly by AVF XI. Atlas Venture Associates XI, L.P., ("AVA XI LP") is the general partner of AVF XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVF XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 22:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | ConversionSeries B Preferred Stock · Derivative | 722,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-037461 · a4.xml · derivative · entry 5 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 235,099 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F5 · ownership.nature: These shares are owned directly by AVO I. Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVO I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVO I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 22:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | ConversionSeries A Preferred Stock · Derivative | 10,666,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-037461 · a4.xml · derivative · entry 4 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 3,469,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F2 · derivative.exercise_date: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F2 · derivative.expiration_date: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F4 · ownership.nature: These shares are owned directly by AVF XI. Atlas Venture Associates XI, L.P., ("AVA XI LP") is the general partner of AVF XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVF XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 22:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | PurchaseCommon Stock | 270,000 | $16.00 | $4,320,000.00 |
DisclosureSEC source: 0001104659-19-037461 · a4.xml · nonDerivative · entry 3 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 505,099 F6 · shares: On June 24, 2019, AVO I purchased 270,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering. F5 · ownership.nature: These shares are owned directly by AVO I. Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVO I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVO I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 22:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | ConversionCommon Stock | 235,099 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-037461 · a4.xml · nonDerivative · entry 2 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 235,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the total number of shares of common stock received by Atlas Opportunity Fund I, L.P. ("AVO I") upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · price: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F5 · ownership.nature: These shares are owned directly by AVO I. Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVO I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims Section 16 beneficial ownership of the securities held by AVO I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 22:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | ConversionCommon Stock | 3,469,759 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-037461 · a4.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,469,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the total number of shares of common stock received by Atlas Venture Fund XI, L.P. ("AVF XI") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · price: All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date. F4 · ownership.nature: These shares are owned directly by AVF XI. Atlas Venture Associates XI, L.P., ("AVA XI LP") is the general partner of AVF XI. Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVF XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.